LNA ASO mixmers that reach heart, muscle, lung, retina, and kidney after simple subcutaneous dosing. AI-guided design from target to optimized lead.
Three acquisitions totaling ~$15B validated exactly the capabilities Elenae unifies: Cardior ($1.1B, Novo Nordisk) for cardiac miRNA with LNA mixmer chemistry. Regulus ($1.7B, Novartis) for kidney miRNA. Avidity ($12B, Novartis) for muscle and cardiac delivery. The strategic acquisition window is open.
See how our platform unifies these capabilities →Presenting at UC Irvine. Series A platform story: AI-guided ASO design engine with extrahepatic reach.
Scored 25 (high consensus) for anti-miR-128 heart failure program. Funding decision pending.
Former Partner at The Column Group brings deep biotech venture and board experience to guide Elenae's Series A strategy.